<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112113</article-id><article-id pub-id-type="publisher-id">ACM-40741</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_55195171.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  基于“高血压达标中心”管理模式下高血压患者的治疗效果研究
  Effects of Hypertension Center-Based Management on Blood Pressure in Hypertension Patients
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>晓东</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>桂霞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>俊杰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>世宇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>初</surname><given-names>玉祥</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>海初</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff4"><addr-line>青岛大学附属医院心血管内科，山东 青岛</addr-line></aff><aff id="aff5"><addr-line>平度市第三人民医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>794</fpage><lpage>803</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨基于“高血压达标中心”管理模式(简称“达标中心”模式)对高血压患者的血压控制效果、用药依从性及生活质量的影响。方法：选取2019年4月~2019年12月期间就诊于青岛大学附属心血管病医院高血压达标中心的307例高血压患者作为试验组，同期未加入“达标中心”管理模式的267例高血压患者作为对照组，进行前瞻性研究。试验组按照“达标中心”模式及流程进行管理，对照组按医院门诊常规诊疗处理；根据两组患者的病情每1~3个月随访1次，共随访6个月，比较两组患者经不同管理模式前后的血压控制效果、用药依从性评价(MMAS-8)、生活质量自评表(SF-36)、抑郁评价(PHQ-9)和焦虑评价(GAD-7)。结果：管理6个月后，试验组血压控制率较对照组高(90.55%比53.93%，P &lt; 0.05),试验组收缩压下降值较对照组高[(28.90 &#177; 16.17) mmHg比(22.20 &#177; 19.12) mmHg，P &lt; 0.05]；两组患者用药依从性均高于管理前，且试验组高于对照组(P &lt; 0.05)；两组患者SF-36评分表中除躯体疼痛无统计学差异外，余7项条目在试验组评分更高且具有统计学差异(P &lt; 0.05)；两组患者在管理后抑郁、焦虑评分均有所下降，但试验组下降更加明显(P &lt; 0.05)。多元线性回归分析示，“达标中心”模式与收缩压变化显著相关，相关系数为−5.8 (P &lt; 0.05)。结论：“达标中心”模式对高血压病人血压控制效果明显，有效的提高患者的用药依从性，改善患者的生活质量。
    Objective: To explore the influence of the management model based on “Hypertension Center” (referred to as “center” management model) on blood pressure control effect, medication adherence, and quality of life in hypertension patients. Methods: Selected 307 hypertensive patients who were in the Hypertension Center of the Cardiovascular Hospital of Qingdao University from April 2019 to December 2019 as the experimental group, and 267 hypertensive patients who did not join the “center” management model during the same period were selected as controls group. And this study conducted a prospective study on the above patients. The test group was managed in accordance with the “center” management model and process, and the control group was treated according to the routine diagnosis and treatment of the hospital; according to the condition of the two groups of patients, the patients were followed up every 1~3 months for a total of 6 months. This study compared the blood pressure control effect, medication adherence evaluation (MMAS-8), quality of life self-assessment form (SF-36), depression evaluation (PHQ-9) and anxiety evaluation (GAD-7). Results: After 6 months of management, the blood pressure control rate of the test group was higher than that of the control group (90.55% vs. 53.93%, P &lt; 0.05), and the drop of the systolic blood pressure in the test group was higher than that of the control group [(28.90 &#177; 16.17) mmHg vs. (22.20 &#177; 19.12) mmHg, P &lt; 0.05]. The medication adherence of the two groups of patients was higher than before the management, and the experimental group was higher than the control group (P &lt; 0.05). Except for no statistical difference in body pain in the SF-36 score of the two groups of patients, the remaining 7 items in the test group scored higher and had statistical differences (P &lt; 0.05). The depression and anxiety scores of the two groups of patients decreased after management, but the decline in the experimental group was more significant (P &lt; 0.05). Multivariate linear regression analysis showed that the “center” management model was significantly related to changes in systolic blood pressure, with a correlation coefficient of −5.8 (P &lt; 0.05). Conclusion: The “center” management model has a significant effect on blood pressure control in hypertensive patients. It can effectively improve the patient’s medication adherence and improve the patient’s quality of life. 
  
 
</p></abstract><kwd-group><kwd>高血压，管理模式，生活质量，用药依从性, Hypertension</kwd><kwd> Management Model</kwd><kwd> Quality of Life</kwd><kwd> Medication Adherence</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨基于“高血压达标中心”管理模式(简称“达标中心”模式)对高血压患者的血压控制效果、用药依从性及生活质量的影响。方法：选取2019年4月~2019年12月期间就诊于青岛大学附属心血管病医院高血压达标中心的307例高血压患者作为试验组，同期未加入“达标中心”管理模式的267例高血压患者作为对照组，进行前瞻性研究。试验组按照“达标中心”模式及流程进行管理，对照组按医院门诊常规诊疗处理；根据两组患者的病情每1~3个月随访1次，共随访6个月，比较两组患者经不同管理模式前后的血压控制效果、用药依从性评价(MMAS-8)、生活质量自评表(SF-36)、抑郁评价(PHQ-9)和焦虑评价(GAD-7)。结果：管理6个月后，试验组血压控制率较对照组高(90.55%比53.93%，P &lt; 0.05),试验组收缩压下降值较对照组高[(28.90 &#177; 16.17) mmHg比(22.20 &#177; 19.12) mmHg，P &lt; 0.05]；两组患者用药依从性均高于管理前，且试验组高于对照组(P &lt; 0.05)；两组患者SF-36评分表中除躯体疼痛无统计学差异外，余7项条目在试验组评分更高且具有统计学差异(P &lt; 0.05)；两组患者在管理后抑郁、焦虑评分均有所下降，但试验组下降更加明显(P &lt; 0.05)。多元线性回归分析示，“达标中心”模式与收缩压变化显著相关，相关系数为−5.8 (P &lt; 0.05)。结论：“达标中心”模式对高血压病人血压控制效果明显，有效的提高患者的用药依从性，改善患者的生活质量。</p></sec><sec id="s2"><title>关键词</title><p>高血压，管理模式，生活质量，用药依从性</p></sec><sec id="s3"><title>Effects of Hypertension Center-Based Management on Blood Pressure in Hypertension Patients<sup> </sup></title><p>Xiaodong Zhang<sup>1</sup>, Guixia Sun<sup>2</sup>, Tao Wang<sup>3</sup>, Junjie Guo<sup>2</sup>, Shiyu Zhang<sup>1</sup>, Yuxiang Chu<sup>4</sup>, Haichu Yu<sup>2*</sup></p><p><sup>1</sup>Medical Department, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>3</sup>The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao Shandong</p><p><sup>4</sup>Pingdu Third People’s Hospital, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/52-1571933x5_hanspub.png" /></p><p>Received: Jan. 25<sup>th</sup>, 2021; accepted: Feb. 9<sup>th</sup>, 2021; published: Feb. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/52-1571933x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the influence of the management model based on “Hypertension Center” (referred to as “center” management model) on blood pressure control effect, medication adherence, and quality of life in hypertension patients. Methods: Selected 307 hypertensive patients who were in the Hypertension Center of the Cardiovascular Hospital of Qingdao University from April 2019 to December 2019 as the experimental group, and 267 hypertensive patients who did not join the “center” management model during the same period were selected as controls group. And this study conducted a prospective study on the above patients. The test group was managed in accordance with the “center” management model and process, and the control group was treated according to the routine diagnosis and treatment of the hospital; according to the condition of the two groups of patients, the patients were followed up every 1~3 months for a total of 6 months. This study compared the blood pressure control effect, medication adherence evaluation (MMAS-8), quality of life self-assessment form (SF-36), depression evaluation (PHQ-9) and anxiety evaluation (GAD-7). Results: After 6 months of management, the blood pressure control rate of the test group was higher than that of the control group (90.55% vs. 53.93%, P &lt; 0.05), and the drop of the systolic blood pressure in the test group was higher than that of the control group [(28.90 &#177; 16.17) mmHg vs. (22.20 &#177; 19.12) mmHg, P &lt; 0.05]. The medication adherence of the two groups of patients was higher than before the management, and the experimental group was higher than the control group (P &lt; 0.05). Except for no statistical difference in body pain in the SF-36 score of the two groups of patients, the remaining 7 items in the test group scored higher and had statistical differences (P &lt; 0.05). The depression and anxiety scores of the two groups of patients decreased after management, but the decline in the experimental group was more significant (P &lt; 0.05). Multivariate linear regression analysis showed that the “center” management model was significantly related to changes in systolic blood pressure, with a correlation coefficient of −5.8 (P &lt; 0.05). Conclusion: The “center” management model has a significant effect on blood pressure control in hypertensive patients. It can effectively improve the patient’s medication adherence and improve the patient’s quality of life.</p><p>Keywords:Hypertension, Management Model, Quality of Life, Medication Adherence</p><disp-formula id="hanspub.40741-formula79"><graphic xlink:href="//html.hanspub.org/file/52-1571933x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/52-1571933x8_hanspub.png" /> <img src="//html.hanspub.org/file/52-1571933x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>原发性高血压是人类最常见的慢性病，全球每年有1040万人死于高血压疾病，血压升高仍是造成死亡的主要原因 [<xref ref-type="bibr" rid="hanspub.40741-ref1">1</xref>]。2015年的一项调查指出我国高血压患者知晓率、治疗率和控制率分别为51.6%、45.8%和16.8% [<xref ref-type="bibr" rid="hanspub.40741-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref3">3</xref>]，总体仍处于较低水平，这显示了传统治疗的防治效果较差。为此需要一种新型高血压管理模式，形成一种特色诊疗体系，同时随着互联网的普及，其丰富的功能和巨大的用户群使得移动互联网健康技术成为一种新型的、潜在的高血压管理治疗工具 [<xref ref-type="bibr" rid="hanspub.40741-ref4">4</xref>]。本研究分析“达标中心”模式下高血压患者管理的效果，为临床提高高血压患者血压达标率及生活质量提供参考。</p></sec><sec id="s6"><title>2. 对象与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选取2019年4月~2019年12月期间就诊于青岛大学附属心血管病院高血压达标中心的307例高血压患者作为试验组，同期未加入“达标中心”模式的267例高血压患者作为对照组。纳入标准：按照《中国高血压防治指南2018》诊断为原发性高血压、年龄18至85岁的患者；能够使用血压计进行自我监测；具有提供知情同意的能力；自愿参加该研究并承诺坚持到随访结束。排除标准：患有继发性高血压或恶性心律失常(如室性心动过速、心室颤动、三度房室传导阻滞等)的患者；尿毒症、肌酐 &gt; 250 μmol/l；近三个月有急性心脏病史者；严重认知障碍(听力、视力严重下降)、精神病史，生活不能自理者；近一年参加其他类似研究的人员。</p></sec><sec id="s6_2"><title>2.2. 研究方法</title><sec id="s6_2_1"><title>2.2.1. 一般资料采集</title><p>研究实施前，进行基线情况调查，包括年龄、性别、就业情况、文化程度、饮酒史、吸烟史、体重指数、腰围、心率、近期未达标的收缩压、舒张压等人口学资料和疾病特征；并收集血尿酸、肌酐、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯、谷丙转氨酶、谷草转氨酶。</p></sec><sec id="s6_2_2"><title>2.2.2. 分组及管理方法</title><p>试验组(基于“达标中心”模式组，以下简称“达标”组)：严格按照“高血压达标中心”要求建立医联体，本结构为1家牵头医院(三级心血管专科医院)和3家社区医院形成医联体。高血压达标中心的目标是“规范我国高血压的诊治和管理，提高高血压的知晓率、治疗率和控制率，最大限度地降低心血管发病和死亡的总体危险”。培训与教育工作是高血压达标中心建设的重要工作内容和职责，包括针对医院领导、医疗管理、行政管理人员的培训，同时包括对牵头医院及卫星医院的专业医师和护士的培训。在患者的诊治方面，制定患者达标路径及方案，规范高血压诊治流程；加强基层医师培训，完善双向转诊流程；加强患者教育，提高患者对高血压认知及依从性；搭建随访管理云平台；加强患者分级随访管理，危险等级越高，随访及干预频率越高(血压未达标、危险等级高的患者一月至少一次，已达标、危险等级低的患者一至三个月一次)；有条件的患者可进入微信管理群，由医师推送高血压相关知识，并对群内患者提出的问题进行答疑。将随访结果记录至云平台，并行药物方案调整。对参与者实施有效的自我管理，形成健康的生活方式。</p><p>对照组(常规管理组)：门诊就诊接受常规治疗，同时进行高血压健康教育宣讲及知识普及，鼓励患者自测家庭血压，在随访中，将他们的近期家庭血压记录在病历中，并给予个性化建议。</p></sec></sec><sec id="s6_3"><title>2.3. 观察指标及评价标准</title><sec id="s6_3_1"><title>2.3.1. 血压情况评价</title><p>与基线血压相比，患者收缩压、舒张压6个月前后的变化情况，根据6个月后的血压情况，计算血压控制率，标准为：收缩压 &lt; 140 mmHg且舒张压 &lt; 90 mmHg [<xref ref-type="bibr" rid="hanspub.40741-ref2">2</xref>]。</p></sec><sec id="s6_3_2"><title>2.3.2. 用药依从性评价</title><p>采用中文版Morisky服药依从性量表(Eight-item Morisky Medication Adherence Scale, MMAS-8)，是被广泛接受的用药依从性评价工具 [<xref ref-type="bibr" rid="hanspub.40741-ref5">5</xref>]。MMAS-8总计8个条目，评估纳入研究的高血压患者用药依从性，总分8分。其中1~7题备选答案为“是”、“否”，答“是”计分0分，答“否”计分1分，第5条目反向计分；第8条目采用Likert5级评分法，备选答案为“从不”“几乎”“不”“有时”“总是”，分别计分1.00、0.75、0.50、0.25、0.00分。各条目计分之和为总分。8分为依从性好，6~8分为依从性中等，6分以下为依从性差。</p></sec><sec id="s6_3_3"><title>2.3.3. 生活质量评价</title><p>采用由美国医学研究组在医疗结局研究量表(medical outcomes study-short form, MOS SF)的基础上研制而来的生活质量自评表SF-36 [<xref ref-type="bibr" rid="hanspub.40741-ref6">6</xref>]，在国际上被普遍认可并广泛应用，通过观察生理功能(PF)、生理职能(RP)、躯体疼痛(BP)、总体健康状况(GH)、精力(VT)、社会功能(SF)、情感职能(RE)和精神健康(MH)共8个领域，来评定患者的生活质量水平，各项总分均为100分，得分越高，生活质量越好。</p></sec><sec id="s6_3_4"><title>2.3.4. 抑郁量表(PHQ-9)</title><p>该表基于美国精神疾病诊断与统计手册(DSM-IV)制定的抑郁自评工具 [<xref ref-type="bibr" rid="hanspub.40741-ref7">7</xref>]，评价患者过去2周感受，共9个四分类条目组成，分别为“完全不会”“好几天”“超过一周”“几乎每天”，相应分数分别为0、1、2、3，总分27分，0~4分提示正常；5~9分提示有轻度抑郁，10~14分提示有中度抑郁，15~27分提示有重度抑郁。</p></sec><sec id="s6_3_5"><title>2.3.5. 焦虑量表(GAD-7)</title><p>该表基于美国精神疾病诊断与统计手册(DSM-IV)建立的焦虑自评量表 [<xref ref-type="bibr" rid="hanspub.40741-ref8">8</xref>]，由7个四分类条目组成，分别为“完全不会”“好几天”“超过一周”“几乎每天”，相应分数分别为0、1、2、3，总分21分，0~4分提示正常；5~9分提示有轻度焦虑，10~14分提示有中度焦虑，15~21分提示有重度焦虑。</p></sec></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>应用SPSS 26.0统计软件进行数据统计分析。计量资料采用均数 &#177; 标准差( x &#175; &#177; s)表示，计数资料以百分率(%)表示。若计量资料满足正态分布且方差齐，采用t检验；若计量资料不符合正态分布则采用秩和检验；计数资料采用c<sup>2</sup>检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组患者一般资料比较</title><p>两组患者在年龄、性别、就业情况、文化程度、个人饮酒、吸烟史、BMI、腰围、心率、收缩压、舒张压等人口学资料、疾病特征和血液生化指标比较，均无统计学差异(P &gt; 0.05)，见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of basic data between the two groups ( x &#175; &#177; s, number and percentage (%)</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >对照组(n = 267)</th><th align="center" valign="middle" >试验组(n = 307)</th><th align="center" valign="middle" >c<sup>2</sup>/Z</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >61.81 &#177; 9.33</td><td align="center" valign="middle" >62.27 &#177; 9.36</td><td align="center" valign="middle" >−0.820</td><td align="center" valign="middle" >0.412</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男性</td><td align="center" valign="middle" >142 (53.2)</td><td align="center" valign="middle" >154 (50.2)</td><td align="center" valign="middle" >0.522</td><td align="center" valign="middle" >0.470</td></tr><tr><td align="center" valign="middle" >女性</td><td align="center" valign="middle" >125 (46.8)</td><td align="center" valign="middle" >153 (49.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >就业情况</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >在业</td><td align="center" valign="middle" >94 (35.2)</td><td align="center" valign="middle" >93 (30.3)</td><td align="center" valign="middle" >1.57</td><td align="center" valign="middle" >0.210</td></tr><tr><td align="center" valign="middle" >退休或无业</td><td align="center" valign="middle" >173 (64.8)</td><td align="center" valign="middle" >214 (69.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >文化程度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >初中及以下</td><td align="center" valign="middle" >116 (43.4)</td><td align="center" valign="middle" >127 (41.4)</td><td align="center" valign="middle" >0.252</td><td align="center" valign="middle" >0.615</td></tr><tr><td align="center" valign="middle" >高中及以上</td><td align="center" valign="middle" >151 (56.6)</td><td align="center" valign="middle" >180 (58.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >饮酒</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >78 (29.2)</td><td align="center" valign="middle" >106 (34.5)</td><td align="center" valign="middle" >1.852</td><td align="center" valign="middle" >0.174</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >189 (70.8)</td><td align="center" valign="middle" >201 (65.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >吸烟</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >67 (25.1)</td><td align="center" valign="middle" >80 (26.1)</td><td align="center" valign="middle" >0.070</td><td align="center" valign="middle" >0.792</td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >200 (74.9)</td><td align="center" valign="middle" >227 (73.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >BMI (kg/m<sup>2</sup>)</td><td align="center" valign="middle" >27.76 &#177; 20.49</td><td align="center" valign="middle" >26.96 &#177; 13.05</td><td align="center" valign="middle" >−0.675</td><td align="center" valign="middle" >0.500</td></tr><tr><td align="center" valign="middle" >腰围(cm)</td><td align="center" valign="middle" >91.45 &#177; 12.24</td><td align="center" valign="middle" >91.36 &#177; 10.00</td><td align="center" valign="middle" >−0.915</td><td align="center" valign="middle" >0.360</td></tr><tr><td align="center" valign="middle" >心率(次/分)</td><td align="center" valign="middle" >69.41 &#177; 12.76</td><td align="center" valign="middle" >69.13 &#177; 9.66</td><td align="center" valign="middle" >−0.088</td><td align="center" valign="middle" >0.930</td></tr><tr><td align="center" valign="middle" >血尿酸(μmol/L)</td><td align="center" valign="middle" >339.84 &#177; 78.95</td><td align="center" valign="middle" >341.26 &#177; 85.48</td><td align="center" valign="middle" >−0.067</td><td align="center" valign="middle" >0.947</td></tr><tr><td align="center" valign="middle" >肌酐(μmol/L)</td><td align="center" valign="middle" >68.80 &#177; 14.85</td><td align="center" valign="middle" >70.25 &#177; 17.35</td><td align="center" valign="middle" >−0.864</td><td align="center" valign="middle" >0.388</td></tr><tr><td align="center" valign="middle" >总胆固醇(mmol/L)</td><td align="center" valign="middle" >4.96 &#177; 1.26</td><td align="center" valign="middle" >4.95 &#177; 1.20</td><td align="center" valign="middle" >−0.214</td><td align="center" valign="middle" >0.831</td></tr><tr><td align="center" valign="middle" >低密度脂蛋白(mmol/L)</td><td align="center" valign="middle" >3.21 &#177; 1.03</td><td align="center" valign="middle" >3.29 &#177; 1.13</td><td align="center" valign="middle" >−0.679</td><td align="center" valign="middle" >0.497</td></tr><tr><td align="center" valign="middle" >高密度脂蛋白(mmol/L)</td><td align="center" valign="middle" >1.31 &#177; 0.44</td><td align="center" valign="middle" >1.32 &#177; 0.40</td><td align="center" valign="middle" >−1.115</td><td align="center" valign="middle" >0.265</td></tr><tr><td align="center" valign="middle" >甘油三酯(mmol/L)</td><td align="center" valign="middle" >1.91 &#177; 1.97</td><td align="center" valign="middle" >1.91 &#177; 1.59</td><td align="center" valign="middle" >−1.739</td><td align="center" valign="middle" >0.082</td></tr><tr><td align="center" valign="middle" >谷丙转氨酶(U/L)</td><td align="center" valign="middle" >25.15 &#177; 25.31</td><td align="center" valign="middle" >23.08 &#177; 13.43</td><td align="center" valign="middle" >−0.458</td><td align="center" valign="middle" >0.647</td></tr><tr><td align="center" valign="middle" >谷草转氨酶(U/L)</td><td align="center" valign="middle" >22.85 &#177; 17.85</td><td align="center" valign="middle" >20.95 &#177; 7.14</td><td align="center" valign="middle" >−0.305</td><td align="center" valign="middle" >0.760</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 两组患者基本资料比较( x &#175; &#177; s，例数及百分率(%))</p></sec><sec id="s7_2"><title>3.2. 管理前后两组患者血压及控制率、服药依从性比较</title><p>管理6个月后，两组患者的收缩压、舒张压均低于基线，差异具有统计学意义(P &lt; 0.05)；试验组收缩压低于对照组，血压控制率高于对照组，差异具有统计学意义(P &lt; 0.05)；两组患者用药依从性较基线均有所升高，但试验组用药依从性评分升高更加明显，差异具有统计学意义(P &lt; 0.05)，见表2。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of blood pressure level, control rate and medication adherence between the two groups before and after management ( x &#175; &#177; s</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >对照组(n = 267)</th><th align="center" valign="middle" >试验组(n = 307)</th><th align="center" valign="middle" >Z、c<sup>2</sup>/P</th></tr></thead><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >管理前</td><td align="center" valign="middle" >163.27 &#177; 16.12</td><td align="center" valign="middle" >161.61 &#177; 15.44</td><td align="center" valign="middle" >−1.469/0.142</td></tr><tr><td align="center" valign="middle" >管理后</td><td align="center" valign="middle" >141.07 &#177; 14.50</td><td align="center" valign="middle" >131.61 &#177; 10.27</td><td align="center" valign="middle" >−8.393/0.000</td></tr><tr><td align="center" valign="middle" >变化值</td><td align="center" valign="middle" >−22.20 &#177; 19.12</td><td align="center" valign="middle" >−28.90 &#177; 16.17</td><td align="center" valign="middle" >−4.349/0.000</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >舒张压(mmHg)</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >管理前</td><td align="center" valign="middle" >89.83 &#177; 13.44</td><td align="center" valign="middle" >87.89 &#177; 12.70</td><td align="center" valign="middle" >−1.545/0.122</td></tr><tr><td align="center" valign="middle" >管理后</td><td align="center" valign="middle" >80.48 &#177; 6.92</td><td align="center" valign="middle" >77.64 &#177; 6.37</td><td align="center" valign="middle" >−4.759/0.000</td></tr><tr><td align="center" valign="middle" >变化值</td><td align="center" valign="middle" >−9.36 &#177; 10.34</td><td align="center" valign="middle" >−10.01 &#177; 10.24</td><td align="center" valign="middle" >−1.028/0.304</td></tr><tr><td align="center" valign="middle" >血压控制率(%)</td><td align="center" valign="middle" >53.93</td><td align="center" valign="middle" >90.55</td><td align="center" valign="middle" >98.372/0.000</td></tr><tr><td align="center" valign="middle" >单片复方制剂使用率(%)</td><td align="center" valign="middle" >32.2</td><td align="center" valign="middle" >54.1</td><td align="center" valign="middle" >27.713/0.000</td></tr><tr><td align="center" valign="middle" >用药依从性</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >管理前</td><td align="center" valign="middle" >6.56 &#177; 1.24</td><td align="center" valign="middle" >6.51 &#177; 1.38</td><td align="center" valign="middle" >−0.243/0.808</td></tr><tr><td align="center" valign="middle" >管理后</td><td align="center" valign="middle" >6.84 &#177; 0.94</td><td align="center" valign="middle" >7.09 &#177; 1.06</td><td align="center" valign="middle" >−3.935/0.000</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 两组患者管理前后两组血压水平、控制率及用药依从性比较( x &#175; &#177; s)</p></sec><sec id="s7_3"><title>3.3. 管理前后两组患者生活质量评分、抑郁评分及焦虑评分比较</title><p>管理6个月后，两组患者SF-36评价除躯体疼痛外，余7项指标均有统计学差异(P &lt; 0.05)；两组患者PHQ-9、GAD-7评分均较管理前下降，但干预后两组差异具有统计学意义(P &lt; 0.05)，见表3。</p><table-wrap-group id="3"><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of SF-36, PHQ-9 and GAD-7 scores between the two groups before and after management ( x &#175; &#177; s, point</title></caption><table-wrap id="3_1"><table><tbody><thead><tr><th align="center" valign="middle" >维度</th><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >干预前</th><th align="center" valign="middle" >干预后</th></tr></thead><tr><td align="center" valign="middle" >生理功能(PF)</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >62.62 &#177; 7.43</td><td align="center" valign="middle" >63.36 &#177; 6.97</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >63.05 &#177; 9.58</td><td align="center" valign="middle" >65.70 &#177; 8.74</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.549/0.583</td><td align="center" valign="middle" >−4.111/0.000</td></tr><tr><td align="center" valign="middle" >生理职能(RP)</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >62.45 &#177; 19.19</td><td align="center" valign="middle" >65.79 &#177; 19.66</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >62.95 &#177; 19.73</td><td align="center" valign="middle" >69.32 &#177; 18.58</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.424/0.671</td><td align="center" valign="middle" >−2.490/0.013</td></tr><tr><td align="center" valign="middle" >躯体疼痛(BP)</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >59.97 &#177; 19.59</td><td align="center" valign="middle" >61.71 &#177; 19.17</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >60.23 &#177; 18.64</td><td align="center" valign="middle" >63.11 &#177; 118.60</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.174/0.862</td><td align="center" valign="middle" >−1.196/0.232</td></tr><tr><td align="center" valign="middle" >总体健康(GH)</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >59.39 &#177; 14.95</td><td align="center" valign="middle" >59.33 &#177; 13.85</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >58.31 &#177; 15.81</td><td align="center" valign="middle" >63.75 &#177; 13.65</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−1.097/0.273</td><td align="center" valign="middle" >−3.900/0.000</td></tr><tr><td align="center" valign="middle" >精力(VT)</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >66.72 &#177; 10.36</td><td align="center" valign="middle" >67.71 &#177; 8.52</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >67.65 &#177; 8.89</td><td align="center" valign="middle" >71.24 &#177; 7.70</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.823/0.410</td><td align="center" valign="middle" >−5.238/0.000</td></tr><tr><td align="center" valign="middle" >社会功能(SF)</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >89.84 &#177; 10.71</td><td align="center" valign="middle" >90.85 &#177; 9.12</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >88.46 &#177; 11.49</td><td align="center" valign="middle" >92.18 &#177; 9.59</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−1.429/0.153</td><td align="center" valign="middle" >−2.214/0.027</td></tr></tbody></table></table-wrap><table-wrap id="3_2"><table><tbody><thead><tr><th align="center" valign="middle" >情感职能(RE)</th><th align="center" valign="middle" >对照组</th><th align="center" valign="middle" >267</th><th align="center" valign="middle" >76.28 &#177; 27.33</th><th align="center" valign="middle" >74.94 &#177; 27.75</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >75.03 &#177; 26.11</td><td align="center" valign="middle" >80.24 &#177; 23.81</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.873/0.383</td><td align="center" valign="middle" >−2.053/0.040</td></tr><tr><td align="center" valign="middle" >精神健康(MH)</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >72.48 &#177; 12.78</td><td align="center" valign="middle" >72.68 &#177; 11.65</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >71.66 &#177; 11.91</td><td align="center" valign="middle" >75.55 &#177; 10.93</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.956/0.339</td><td align="center" valign="middle" >−3.528/0.000</td></tr><tr><td align="center" valign="middle" >抑郁筛查</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >8.15 &#177; 5.54</td><td align="center" valign="middle" >7.76 &#177; 4.53</td></tr><tr><td align="center" valign="middle" >(PHQ-9)</td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >7.93 &#177; 5.54</td><td align="center" valign="middle" >7.21 &#177; 4.77</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.537/0.591</td><td align="center" valign="middle" >−2.195/0.028</td></tr><tr><td align="center" valign="middle" >焦虑筛查</td><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >8.85 &#177; 5.24</td><td align="center" valign="middle" >8.24 &#177; 4.29</td></tr><tr><td align="center" valign="middle" >(GAD-7)</td><td align="center" valign="middle" >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >8.66 &#177; 5.25</td><td align="center" valign="middle" >7.35 &#177; 4.17</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Z/P</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >−0.501/0.616</td><td align="center" valign="middle" >−2.619/0.000</td></tr></tbody></table></table-wrap></table-wrap-group><p>表3. 两组患者管理前后SF-36、PHQ-9、GAD-7评分比较( x &#175; &#177; s，分)</p></sec><sec id="s7_4"><title>3.4. 回归分析</title><p>单因素线性回归分析提示“达标中心”模式与患者的收缩压下降幅度变化显著相关，调整患者年龄、性别、单片复方制剂用药后，“达标中心”模式仍显著相关，相关系数为−5.8，见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Regression analysis of “Hypertension Center” model and changes of systolic blood pressur</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  ></th><th align="center" valign="middle"  colspan="2"  >单因素</th><th align="center" valign="middle"  colspan="2"  >多因素</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >组别</td><td align="center" valign="middle" >n</td><td align="center" valign="middle" >β (95%CI)</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >β (95%CI)</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle"  colspan="2"  >对照组</td><td align="center" valign="middle" >267</td><td align="center" valign="middle" >Ref</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >Ref</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="2"  >试验组</td><td align="center" valign="middle" >307</td><td align="center" valign="middle" >−6.7 (−9.6, −3.8)</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >−5.8 (−8.8, −2.9)</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表4. “达标中心”模式与收缩压变化值回归分析</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>高血压是一种常见的慢性病，也是心脑血管疾病死亡的主要原因 [<xref ref-type="bibr" rid="hanspub.40741-ref9">9</xref>]。预防和控制高血压，是遏制我国心脑血管疾病流行的核心策略，基层医疗卫生机构是高血压管理的“主战场” [<xref ref-type="bibr" rid="hanspub.40741-ref10">10</xref>]。通过防控措施降低高血压患者的收缩压及舒张压水平，可明显减少心脑血管等疾病的发生，提高患者生存质量，降低患者负担 [<xref ref-type="bibr" rid="hanspub.40741-ref11">11</xref>]。传统社区高血压管理健康教育模式主要采用面对面宣教、授课等方式，不仅会花费患者及医护人员的时间及精力，而且，由于各种原因使得病人的积极性不高，参与率低，不利于防治工作的开展。而“达标中心”模式可使患者更便捷的在家中获取个性化的健康教育，信息技术的发展也让患者通过网络和医生或其他病人进行交流讨论，分享彼此的治疗经验，提高解决问题的速度，在做出改善生活方式的同时增强患者信心，有利于疾病的控制 [<xref ref-type="bibr" rid="hanspub.40741-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref14">14</xref>]。</p><p>本研究显示“达标中心”模式可以显著降低高血压患者收缩压及舒张压水平(P &lt; 0.05)。与基线相比，“达标中心”模式组和对照组收缩压及舒张压水平均有改善，但“达标中心”模式组比对照组改善更加明显，收缩压幅度下降了(28.90 &#177; 16.17) mmHg。单因素回归分析提示“达标中心”模式与收缩压变化显著相关，在调整患者年龄、性别、用药因素后进行多元线性回归分析，“达标中心”模式管理与收缩压变化仍显著相关，相关系数为−5.8 (95%CI −8.7~−2.8, P &lt; 0.05)。据报道截止到2025年，全球高血压慢性病患者数量将会达到15.6亿人，成为全球人口死亡的重要原因之一 [<xref ref-type="bibr" rid="hanspub.40741-ref15">15</xref>]。尽管使用降压药物可控制血压，减少冠心病、心力衰竭、卒中等并发症的发病率，但血压控制率仍不理想。本试验中，“达标中心”模式中高血压患者的血压控制率为90.55%，明显高于对照组的控制率53.93%。2018年欧洲心脏病学会/欧洲高血压学会高血压管理指南提出了对高血压患者支持单片复方制剂(SPC)治疗优于自由联合治疗的证据需求 [<xref ref-type="bibr" rid="hanspub.40741-ref16">16</xref>]，一荟萃分析结果显示与自由联合治疗相比，SPC的依从性和持久性普遍更高，达标的患者比例范围为25%至89% [<xref ref-type="bibr" rid="hanspub.40741-ref17">17</xref>]。在“达标中心”模式中，患者用药除需要考虑患者经济及个性化等其他因素之外，优先选用单片复方制剂，在本试验中，“达标中心”模式下患者SPC应用率高达54.1%，高于对照组32.2%，这也是促使血压达标率提高的原因。多因素回归分析提示SPC的应用与收缩压下降显著相关，相关系数为−4.2 (95%CI −7.1~−1.2, P &lt; 0.05)。这表明“达标中心”模式具有明显控制高血压病人血压水平的作用，显著降低患者收缩压水平，提高达标率。</p><p>近年来，医学模式已转变为生物心理社会医学模式，因此在关注患者血压达标的同时，也应当关注患者的生活质量、抑郁、焦虑情况。目前评价患者生活质量、抑郁、焦虑的指标逐渐增多 [<xref ref-type="bibr" rid="hanspub.40741-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref20">20</xref>]。生活质量及抑郁、焦虑指标可全方面衡量患者个体健康，包括患者的生理、心理、社会功能等健康状态。有研究显示高血压患者的生活质量与患者的年龄、学历、血压达标情况和病程等方面有关 [<xref ref-type="bibr" rid="hanspub.40741-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref22">22</xref>]。本研究采用SF-36、PHQ-9、GAD-7量表，分析评价经“达标中心”模式和常规管理模式不同管理后的两组患者的生活质量差别。管理6个月后，与普通管理组相比，经“达标中心”模式管理后的患者SF-36评分中共8个条目中，评分均有升高，但除躯体疼痛(BP)指标(P &gt; 0.05)外，其余7项指标均评分均有统计学差异(P &lt; 0.05)，PHQ-9抑郁评分及GAD-7焦虑评分同样具有统计学差异(P &lt; 0.05)。这提示经“达标”模式管理后的患者生活质量水平较对照组的患者生活质量水平更好，抑郁焦虑状态有所改善。躯体疼痛条目没有统计学差异的原因可能是由于高血压症状与躯体疼痛感觉没有密切相关性。有研究显示慢性病患者的服药不依从性高达50%，且发展中国家可能更高，是慢性疾病管理的一个重大挑战 [<xref ref-type="bibr" rid="hanspub.40741-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref25">25</xref>]。服药依从性与高血压的控制率具有密切关系，服药依从性差是控制率低的主要原因之一 [<xref ref-type="bibr" rid="hanspub.40741-ref26">26</xref>] [<xref ref-type="bibr" rid="hanspub.40741-ref27">27</xref>]。在本研究结果中，管理前两组患者用药依从性基线水平均较高，管理后两组患者用药依从性较前均有提升，但“达标中心”模式组用药依从性评分较入组时提高更加明显且两组具有统计学差异(P &lt; 0.05)，提示经“达标中心”模式管理后的患者对服药依从性更高。另有一项研究表明，新确诊高血压患者的第一年服药依从性约为50%，将近20%的高血压患者首次购药后即停止继续购药 [<xref ref-type="bibr" rid="hanspub.40741-ref28">28</xref>]，本试验中经“达标中心”模式管理的患者服药依从性高，抑郁、焦虑情况改善，可能的原因为医联体内部对包括针对医院领导、医疗管理、行政管理人员及其相关医护人员的培训，促使医院人员提高对患者健康教育的重视，同时定期举行线下及线上高血压健康相关教育，减少了患者对高血压等疾病的抑郁、焦虑的发生，病人的不适感消失，从而提高了患者的生活质量。通过“达标中心”模式管理可提高患者服药和治疗的依从性和治疗满意度，使得高血压的动态干预提前，最终达到提高高血压患者生活质量的目的。</p><p>综上所述，“达标中心”模式对于高血压患者的血压控制率、用药依从性和生活质量等方面均有较大改善，为未来高血压慢病管理提供了一套全新的管理模式。然而，本研究样本量较小，随访时间较短，还需要更大样本量，多中心联合加以证实。</p></sec><sec id="s9"><title>声明</title><p>本研究已通过医院伦理委员会批准。</p></sec><sec id="s10"><title>文章引用</title><p>张晓东,孙桂霞,王 涛,郭俊杰,张世宇,初玉祥,于海初. 基于“高血压达标中心”管理模式下高血压患者的治疗效果研究Effects of Hypertension Center-Based Management on Blood Pressure in Hypertension Patients[J]. 临床医学进展, 2021, 11(02): 794-803. https://doi.org/10.12677/ACM.2021.112113</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40741-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Schneider, R.H., Salerno, J. and Brook, R.D. (2020) 2020 International Society of Hypertension Global Hypertension Practice Guidelines—Lifestyle Modification. Journal of Hypertension, 38, 2340-2341.</mixed-citation></ref><ref id="hanspub.40741-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会中国医师协会高血压专业委员会, 中国医疗保健国际交流促进会高血压分会, 中国老年医学学会高血压分会. 中国高血压防治指南(2018年修订版) [J]. 中国心血管杂志, 2019, 24(1): 24-56. http://dx.chinadoi.cn/10.3969/j.issn.1007-5410.2019.01.002</mixed-citation></ref><ref id="hanspub.40741-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9): 833-854.</mixed-citation></ref><ref id="hanspub.40741-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Li, T., Ding, W., Li, X. and Lin, A. (2019) Mobile Health Technology (WeChat) for the Hierarchical Management of Community Hypertension: Protocol for a Cluster Randomized Controlled Trial. Patient Preference and Adherence, 2019, 1339-1352. &lt;br&gt;https://doi.org/10.2147/PPA.S215719</mixed-citation></ref><ref id="hanspub.40741-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Morisky, D.E., Ang, A., Krousel-Wood, M. and Ward, H.J. (2008) Predictive Validity of a Medication Adherence Measure in an Outpatient Setting. The Journal of Clinical Hypertension, 10, 348-354.  
&lt;br&gt;https://doi.org/10.1111/j.1751-7176.2008.07572.x</mixed-citation></ref><ref id="hanspub.40741-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ware Jr., J.E. and Sherbourne, C.D. (1992) The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual Framework and Item Selection. Medical Care, 30, 473-483. &lt;br&gt;https://doi.org/10.1097/00005650-199206000-00002</mixed-citation></ref><ref id="hanspub.40741-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, W., Bian, Q., Zhao, Y., Li, X., Wang, W.W., Du, J., et al. (2014) Reliability and Validity of the Chinese Version of the Patient Health Questionnaire (PHQ-9) in the General Population. General Hospital Psychiatry, 3, 539-544. 
&lt;br&gt;https://doi.org/10.1016/j.genhosppsych.2014.05.021</mixed-citation></ref><ref id="hanspub.40741-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Spitzer, R.L., Kroenke, K., Williams, J.B. and Löwe, B. (2006) A Brief Measure for Assessing Generalized Anxiety Disorder: the GAD-7. Archives of Internal Medicine, 166, 1092-1097. &lt;br&gt;https://doi.org/10.1001/archinte.166.10.1092</mixed-citation></ref><ref id="hanspub.40741-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., et al. (2013) 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. Blood Press, 22, 193-278.  
&lt;br&gt;https://doi.org/10.3109/08037051.2013.812549</mixed-citation></ref><ref id="hanspub.40741-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">国家基本公共卫生服务项目基层高血压管理办公室, 基层高血压管理专家委员会. 国家基层高血压防治管理指南[J]. 中国循环杂志, 2017, 32(11): 1041-1048.</mixed-citation></ref><ref id="hanspub.40741-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华心血管病杂志, 2011, 39(7): 579-616.</mixed-citation></ref><ref id="hanspub.40741-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cline, R.J. and Haynes, K.M. (2001) Consumer Health Information Seeking on the Internet: The State of the Art. Health Education Research, 16, 671-692. &lt;br&gt;https://doi.org/10.1093/her/16.6.671</mixed-citation></ref><ref id="hanspub.40741-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">吕恒旭, 刁海燕. 网络化健康教育在社区高血压患者自我管理中的应用效果研究[J]. 临床合理用药杂志, 2016, 9(24): 128-130.</mixed-citation></ref><ref id="hanspub.40741-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">沈干, 胡世莲, 吴蕾, 徐维平, 方向, 陈尹, 等. 电话及网络健康教育对中老年居民高血压干预效果评价[J]. 中国临床保健杂志, 2014, 17(6): 563-566.</mixed-citation></ref><ref id="hanspub.40741-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Roger, V.L., Go, A.S., Lloyd-Jones, D.M., Benjamin, E.J., Berry, J.D., Borden, W.B., et al. (2012) Heart Disease and Stroke Statistics—2012 Update: A Report from the American Heart Association. Circulation, 125, e2-e220. 
&lt;br&gt;https://doi.org/10.1161/CIR.0b013e31823ac046</mixed-citation></ref><ref id="hanspub.40741-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Whelton, P.K. and Williams, B. (2018) The 2018 European Society of Cardiology/European Society of Hypertension and 2017 American College of Cardiology/American Heart Association Blood Pressure Guidelines: More Similar Than Different. JAMA, 320, 1749-1750. &lt;br&gt;https://doi.org/10.1001/jama.2018.16755</mixed-citation></ref><ref id="hanspub.40741-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Tsioufis, K., Kreutz, R., Sykara, G., van Vugt, J. and Hassan, T. (2020) Impact of Single-Pill Combination Therapy on Adherence, Blood Pressure Control, and Clinical Outcomes: A Rapid Evidence Assessment of Recent Literature. Journal of Hypertension, 38, 1016-1028. &lt;br&gt;https://doi.org/10.1097/HJH.0000000000002381</mixed-citation></ref><ref id="hanspub.40741-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">潘雁, 叶颖, 朱珺, 龚辉. 应用SF-36量表分析高血压患者生命质量(QOL)的影响因素[J]. 复旦学报(医学版), 2014, 41(2): 205-209+273.</mixed-citation></ref><ref id="hanspub.40741-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">李佳梅, 陈鸿芳, 李换则, 戴蒙, 吕媛. “互联网+”慢性病管理模式在原发性高血压患者中的应用效果[J]. 临床医学研究与实践, 2020, 5(17): 148-149+152.</mixed-citation></ref><ref id="hanspub.40741-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">谭柳春, 潘丽妹, 潘江艳, 贾卫鸿. GAD-7和PHQ-9自评心理测评表评估心内科门诊患者焦虑、抑郁状态[J]. 吉林医学, 2018, 39(12): 2287-2289.</mixed-citation></ref><ref id="hanspub.40741-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Roca-Cusachs, A., Badia, X., Dalfó, A., Gascón, G., Abellán, J., Lahoz, R., et al. (2003) Relationship between Clinical and Therapeutic Variables and Health-Related Quality of Life in Patients with Hypertension. Medicina Clínica, 121, 12-17. &lt;br&gt;https://doi.org/10.1016/S0025-7753(03)74112-8</mixed-citation></ref><ref id="hanspub.40741-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">杨雪巍, 肖楠梓, 金娅娜, 何苗, 唐晓君, 龙倩, 等. 重庆地区原发性高血压患者生命质量及影响因素调查[J]. 复旦学报(医学版), 2015, 42(6): 758-763.</mixed-citation></ref><ref id="hanspub.40741-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">De Geest, S. and Sabate, E. (2003) Adherence to Long-Term Therapies: Evidence for Action. European Journal of Cardiovascular Nursing, 2, 323. &lt;br&gt;https://doi.org/10.1016/S1474-5151(03)00091-4</mixed-citation></ref><ref id="hanspub.40741-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Choudhry, N.K., Dugani, S., Shrank, W.H., Polinski, J.M., Stark, C.E., Gupta, R., et al. (2014) Despite Increased Use and Sales of Statins in India, Per Capita Prescription Rates Remain Far Below High-Income Countries. Health Aff, 33, 273-282. &lt;br&gt;https://doi.org/10.1377/hlthaff.2013.0388</mixed-citation></ref><ref id="hanspub.40741-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Beaglehole, R., Epping-Jordan, J., Patel, V., Chopra, M., Ebrahim, S., Kidd, M., et al. (2008) Improving the Prevention and Management of Chronic Disease in Low-Income and Middle-Income Countries: A Priority for Primary Health Care. Lancet, 372, 940-949. &lt;br&gt;https://doi.org/10.1016/S0140-6736(08)61404-X</mixed-citation></ref><ref id="hanspub.40741-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Shaw, R. and Bosworth, H.B. (2012) Baseline Medication Adherence and Blood Pressure in a 24-Month Longitudinal Hypertension Study. Journal of Clinical Nursing, 21, 1401-1406. &lt;br&gt;https://doi.org/10.1111/j.1365-2702.2011.03859.x</mixed-citation></ref><ref id="hanspub.40741-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">魏海斌, 邓雅琦, 胡园, 谭文扬, 吴一波. 微信精准健康科普对高血压病患者服药依从性的影响[J]. 中国卫生信息管理杂志, 2018, 15(6): 682-684+690.</mixed-citation></ref><ref id="hanspub.40741-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Evans, C.D., Eurich, D.T., Remillard, A.J. and Shevchuk, Y.M. (2012) First-Fill Medication Discontinuations and Nonadherence to Antihypertensive Therapy: An Observational Study. American Journal of Hypertension, 25, 195-203. 
&lt;br&gt;https://doi.org/10.1038/ajh.2011.198</mixed-citation></ref></ref-list></back></article>